Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines

Cancer Research

Volumn 59, Issue 14, 1999, Pages 3329-3332

  Henry, Frédéric ^a   Boisteau, Olivier ^a   Bretaudeau, Laurent ^a   Lieubeau, Blandine ^a   Meflah, Khaled ^a   Grégoire, Marc ^a  

^a INSTITUT DE BIOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD86 ANTIGEN; INTEGRIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY ED3; MONOCLONAL ANTIBODY OX17; MONOCLONAL ANTIBODY OX18; MONOCLONAL ANTIBODY OX33; MONOCLONAL ANTIBODY OX41; MONOCLONAL ANTIBODY OX62; SIALOADHESIN; T LYMPHOCYTE RECEPTOR; TUMOR VACCINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOMATOSIS; CELL CULTURE; DRUG POTENCY; IMMUNE RESPONSE; IMMUNOGENICITY; MYCOPLASMA; NONHUMAN; PHAGOCYTOSIS; PRIORITY JOURNAL; RAT; TREATMENT PLANNING; TUMOR CELL CULTURE; TUMOR REGRESSION; VACCINATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGEN-PRESENTING CELLS; ANTIGENS, NEOPLASM; APOPTOSIS; CANCER VACCINES; COLONIC NEOPLASMS; IMMUNOTHERAPY, ACTIVE; LYMPHOCYTE ACTIVATION; MONOCYTES; PHAGOCYTOSIS; RATS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 0033565513     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., Wunderlich, J. R., Parkhurst, M. R., Kawakami, Y., Seipp, C. A., Einhorn, J. H., and White, D. E. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat. Med., 4: 321-327, 1998.
2. Ashley, D. M., Faiola, B., Nair, S., Hale, L. P., Bigner, D. D., and Gilboa, E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induced antitumor immunity against central nervous system tumors. J. Exp. Med., 186: 1177-1182, 1997.
3. Nestle, F. O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer, R., Burg, G., and Schadendorf, D. Vaccination of melanoma patients with peptide-or tumor lysate-pulsed dendritic cells. Nat. Med., 4: 328-332, 1998.
4. Nair, S. K., Snyder, D., Rouse, B. T., and Gilboa, E. Regression of tumors in mice vaccinated with professional antigen presenting-cells pulsed with tumor extracts. Int. J. Cancer, 70: 706-715, 1997.
5. Boisteau, O., Gautier, F., Cordel, S., Henry, F., Harb, J., Douillard, J-Y., Vallette, F. M., Meflah, K., and Grégoire, M. Apoptosis induced by sodium butyrate treatment increases immunogenicity of a rat colon tumor cell line. Apoptosis, 2: 403-412, 1997.
6. Henry, F., Bretaudeau, L., Barbieux, I., Meflah, K., and Grégoire, M. Induction of antigen presentation by macrophages after phagocytosis of tumour apoptotic cells. Res. Immunol., 149: 673-679, 1998.
7. Kohs, J. S., Levine, J. S. Apoptosis and autoimmunity. Curr. Opin. Nephrol. Hypertens., 6: 259-266, 1997.
8. Inaba, K., Turley, S., Yamaide, F., Iyoda, T., Mahnke, K., Inaba, M., Pack, M., Subklewe, M., Sauter, B., Sheff, D., Albert, M., Bhardwaj, N., Mellman, I., and Steinman, R. M. Efficient presentation of phagocytosed cellular fragments on the major histocompatibility complex class II products of dendritic cells. J. Exp. Med., 188: 2163-2173, 1998.
9. Savill, J. Phagocytic docking without shocking. Nature (Lond.), 392: 442-443, 1998.
10. Bellone, M., Iezzi, G., Rovere, P., Galati, G., Ronchetti, A., Protti, M. P., Davoust, J., Rugarli, C., and Manfredi, A. Processing of engulfed apoptotic bodies yields T cell epitopes. J. Immunol., 159: 5391-5399, 1997.
11. Albert, M. L., Sauter, B., and Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class 1-restricted CTLs. Nature (Lond.), 392: 86-89, 1998.
12. Perrin, P., Cassagnau, E., Burg, C., Patry, Y., Vavasseur, F., Harb, J., LePendu, J., Douillard, J-Y., Galmiche, J-P., Bornet, F., and Meflah, K. An interleukin 2/sodium butyrate combination as immunotherapy for rat colon cancer peritoneal carcinomatosis. Gastroenterology, 107: 1697-1708, 1994.
13. ++-dependent mechanism. J. Exp. Med., 186: 467-472, 1997.
14. Patry, Y., Douillard, J-Y., Meflah, K., and LePendu, J. Immunization against a rat colon carcinoma by sodium butyrate-treated cells but not interleukin 2-secreting cells. Gastroenterology, 109: 1555-1565, 1995.
15. Blottière, H. M., Burg, C., Zennadi, R., Perrin, P., Blanchardie, P., Bara, J., Meflah, K., and Le Pendu, J. Involvement of histo-blood group antigens in the susceptibility of colon carcinoma cells to natural-killer mediated cytotoxicity. Int. J. Cancer, 52: 609-618, 1992.
16. Rovere, P., Vallinoto, C., Bondanza, A., Crosti, M. C., Rescigno, M., Ricciardi-Castagnoli, P., Rugarli, C., and Manfredi, A. A. Bystander apoptosis triggers dendritic cell maturation and antigen-presentation function. J. Immunol., 161: 4467-4471, 1998.
17. 2+ cells. II. Primary mixed-lymphocyte reactions stimulated by Ia+ dendritic cells and Ia-peritoneal exudate cells. Int. Immunol., 1: 517-525, 1989.
18. Brenan, M., and Puklavec, M. The MRC OX-62 antigen: a useful marker in the purification of rat veiled cells with the biochemical properties of an integrin. J. Exp. Med., 175: 1457-1465, 1992.
19. Shimizu, K., Fields, R. C., Gieldin, M., and Mule, J. J. Systemic administration of interleukin 2 enhances the therapeutic efficacy of dendritic cell-based tumor vaccines. Proc. Natl. Acad. Sci. USA, 96: 2268-2273, 1999.
20. Celluzzi, C. M., and Falo, L. D. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol., 160: 3081-3085, 1998.